SCHEMBL2814905

SCHEMBL2814905

CCc1cc(OC)cc(OCC(N)=O)c1-c1nc2ncccn2c1Nc1c(C)cccc1C

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 16/20 0.51
MAPT P10636 14/20 0.51
TP53 P04637 7/20 0.51
MEN1 O00255 1/20 0.44
PTBP1 P26599 1/20 0.44
MAPK1 P28482 1/20 0.44
KMT2A Q03164 1/20 0.44
TUBB4A P04350 1/20 0.42
TUBB P07437 1/20 0.42
TUBA3C P0DPH7 1/20 0.42
TUBA1B P68363 1/20 0.42
TUBA4A P68366 1/20 0.42
TUBB4B P68371 1/20 0.42
TUBB3 Q13509 1/20 0.42
TUBB2A Q13885 1/20 0.42
TUBB8 Q3ZCM7 1/20 0.42
TUBA3E Q6PEY2 1/20 0.42
TUBA1A Q71U36 1/20 0.42
TUBA1C Q9BQE3 1/20 0.42
TUBB6 Q9BUF5 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2814190 0.93 GAA (0.50) GAAMAPTTP53MEN1PTBP1
SCHEMBL2808371 0.91 GAA (0.43) GAAMAPTTP53MEN1PTBP1
SCHEMBL2810034 0.88 GAA (0.58) GAAMAPTTP53MEN1PTBP1
SCHEMBL2291007 0.88 MAPT (0.46) GAAMAPTTP53MEN1MAPK1
SCHEMBL2292032 0.86 MAPT (0.40) GAAMAPTTP53KDM4EALDH1A1
SCHEMBL2290761 0.86 MAPT (0.41) GAAMAPTTP53KDM4EALDH1A1
SCHEMBL2290766 0.83 GAA (0.48) GAAMAPTTP53MAPK1KMT2A
SCHEMBL2287599 0.83 GAA (0.41) GAAMAPTTP53KDM4EALDH1A1
SCHEMBL2289607 0.82 MAPT (0.39) GAAMAPTTP53KDM4EALDH1A1
SCHEMBL2296111 0.82 TRIM33 (0.38) GAAMAPTTP53KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2195322-B1 IMIDAZO[1,2-A]PYRIMIDINE DERIVATIVES FOR TREATING DISEASES SUCH AS DIABETES MERCK PATENT GMBH (DE) 2014-08-06 EP claimed
US-8278312-B2 Imidazo 1,2-a pyrimidine derivatives for the treatment of diseases such as diabetes MERCK Patent Gesellschaft mit beschränkter Haftung (DE) 2012-10-02 US claimed
US-20100249151-A1 IMIDAZO 1, 2-A PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF DISEASES SUCH AS DIABETES Merck Patent Gesellschaft Beschrankter Haftung (DE) 2010-09-30 US claimed
EP-2195322-B1 IMIDAZO[1,2-A]PYRIMIDINE DERIVATIVES FOR TREATING DISEASES SUCH AS DIABETES MERCK PATENT GMBH (DE) 2014-08-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249151-A1 IMIDAZO 1, 2-A PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF DISEASES SUCH AS DIABETES TYMS, CCNT1, INSR GAA 1202/4885MAPT 3889/4885TP53 1417/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.